☆ 4.6 Article

Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)

GENETICS IN MEDICINE (2021)

Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer

Honglin Song et al.

Summary: This study aimed to investigate the contribution of rare deleterious germline variants in candidate genes to ovarian cancer susceptibility. The findings suggest a potential association between PALB2 mutations and increased risk of high-grade serous ovarian cancer, with further research needed to confirm the significance of other genes.

JOURNAL OF MEDICAL GENETICS (2021)

添加到收藏夹

Article Oncology

Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer

Burcu F. Darst et al.

Summary: The study identified a significant association between rare P/LP/D alleles in DNA repair genes such as BRCA2, PALB2, and ATM with aggressive prostate cancer risk, highlighting the importance of these genes in both screening and disease management considerations.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

添加到收藏夹

Article Oncology

TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).

Nadine M. Tung et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Meeting Abstract Oncology

Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes.

Joshua James Gruber et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)

相关参考文献

Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer

Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer

TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).

Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes.

导出引文

分享论文